Alzheimer's Disease (AD), the most common cause of dementia in the elderly, is estimated to affect over 4 million Americans, a number projected to grow in the next few decades. Research progress has led to improved diagnostic accuracy for AD, the development of symptomatic medications, and provision of social and community care networks. However, current treatment options provide only temporary stabilization at best, and the overall cost for care of patients with AD in the USA exceeds $100 billion per year. Further research is essential to make progress in the fight against AD. The UCSD Alzheimer's Disease Research Center (ADRC) has contributed to much research progress in the past 25 years. In order to facilitate and conduct research into the causes, treatment and prevention of AD, the overall Specific Aims of this renewal application for the Center are: 1) To support research efforts by maintaining resources that include cohorts of subjects with normal cognition, AD and other dementias;neuropathology tissue from well-characterized subjects;biological samples and DMA;and to maintain a comprehensive database. 2) To coordinate pilot and research projects related to Alzheimer's Disease, aging or neurodegeneration. 3) To foster professional education and training, as well as educational outreach efforts in the community. 4) To collaborate with other ADCs, with NACC, and with national research efforts related to AD and dementia. The Center will consist of an Administrative Core, a Clinical Core (with a Hispanic Minority Satellite), a Neuropathology Core, a Data and Biostatistics Core, an Education and Information Core. Three research Projects are proposed: 1) Structural MRI analyses to distinguish patients with AD, Dementia with Lewy Bodies (DLB) and Controls. 2) Axonal transport of a-synuclein and the pathogenesis of DLB. 3) Psychometric prediction of the rate of progression of AD and DLB. Three Pilot Project awards will be issued each year. The Center will follow 500 subjects, using annual standard evaluations that include the Uniform Data Set components and will contribute to national research efforts by contributing data to the National Alzheimer's Coordinating Center, and to the Alzheimer's Disease Neuroimaging Initiative (ADNI). ADRC subjects will be offered participation in clinical trials organized by the Alzheimer's Disease Cooperative Study (ADCS) and by pharmaceutical companies. The Center will continue to support innovative research, to train new investigators, and to improve public knowledge and awareness about aging and AD, as well as to provide innovative support efforts for patients and families affected by AD.

Public Health Relevance

AD affects millions of Americans with its risk growing exponentially with age. The AD Centers Program fosters research related to AD and non-AD dementias. The ADRC will enhance the performance of innovative research on AD and related topics, including research that may lead to potential disease modifying therapies or behavioral treatments. It will provide an environment and core resources to enhance research, foster professional and community training, and coordinate interdisciplinary research.

National Institute of Health (NIH)
National Institute on Aging (NIA)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZAG1-ZIJ-4 (J1))
Program Officer
Phelps, Creighton H
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Diego
Schools of Medicine
La Jolla
United States
Zip Code
Edmonds, Emily C; Delano-Wood, Lisa; Clark, Lindsay R et al. (2015) Susceptibility of the conventional criteria for mild cognitive impairment to false-positive diagnostic errors. Alzheimers Dement 11:415-24
Dhungel, Nripesh; Eleuteri, Simona; Li, Ling-Bo et al. (2015) Parkinson's disease genes VPS35 and EIF4G1 interact genetically and converge on ?-synuclein. Neuron 85:76-87
Bangen, Katherine J; Nation, Daniel A; Delano-Wood, Lisa et al. (2015) Aggregate effects of vascular risk factors on cerebrovascular changes in autopsy-confirmed Alzheimer's disease. Alzheimers Dement 11:394-403.e1
Donohue, Michael C; Moghadam, Setareh H; Roe, Allyson D et al. (2015) Longitudinal plasma amyloid beta in Alzheimer's disease clinical trials. Alzheimers Dement 11:1069-79
Edmonds, Emily C; Delano-Wood, Lisa; Galasko, Douglas R et al. (2014) Subjective cognitive complaints contribute to misdiagnosis of mild cognitive impairment. J Int Neuropsychol Soc 20:836-47
Overk, Cassia R; Masliah, Eliezer (2014) Pathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body disease. Biochem Pharmacol 88:508-16
Yu, Peng; Sun, Jia; Wolz, Robin et al. (2014) Operationalizing hippocampal volume as an enrichment biomarker for amnestic mild cognitive impairment trials: effect of algorithm, test-retest variability, and cut point on trial cost, duration, and sample size. Neurobiol Aging 35:808-18
Nuber, Silke; Tadros, Daniel; Fields, Jerel et al. (2014) Environmental neurotoxic challenge of conditional alpha-synuclein transgenic mice predicts a dopaminergic olfactory-striatal interplay in early PD. Acta Neuropathol 127:477-94
Wang, Lina; Das, Utpal; Scott, David A et al. (2014) ?-synuclein multimers cluster synaptic vesicles and attenuate recycling. Curr Biol 24:2319-26
Shi, Min; Liu, Changqin; Cook, Travis J et al. (2014) Plasma exosomal ?-synuclein is likely CNS-derived and increased in Parkinson's disease. Acta Neuropathol 128:639-50

Showing the most recent 10 out of 484 publications